Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474944 | 0.85 | MEN1 (0.34) | — | |
| SCHEMBL4670028 | 0.81 | KDM4E (0.33) | — | |
| SCHEMBL22207950 | 0.77 | KMT2A (0.41) | — | |
| SCHEMBL3818712 | 0.76 | ARG1 (0.32) | — | |
| SCHEMBL2115692 | 0.76 | ARG1 (0.32) | — | |
| SCHEMBL31031980 | 0.74 | MAOA (0.39) | — | |
| SCHEMBL2993885 | 0.74 | TSHR (0.31) | — | |
| SCHEMBL9190966 | 0.74 | GNAI3 (0.37) | ODC1 | |
| SCHEMBL940519 | 0.74 | PAOX (0.32) | ODC1 | |
| SCHEMBL8210559 | 0.74 | PAOX (0.32) | ODC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2010-03-04 | — | — | US | claimed |
| EP-1898943-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | Hadasit Medical Research Services & Development Ltd. (IL) | 2008-03-19 | — | — | EP | claimed |
| WO-2006126188-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2006-11-30 | — | — | WO | claimed |
| US-20040116655-A1 | Novel polypeptides and anti-hiv drugs containing the same | BIOKINE THERAPEUTICS LTD. (IL) | 2004-06-17 | — | — | US | claimed |
| EP-1323730-A1 | NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME | SEIKAGAKU CORPORATION (JP) | 2003-07-02 | — | — | EP | claimed |
| EP-3011961-B1 | 4F-BENZOYL-TN14003 FOR THE MOBILISATION OF HEMATOPOIETIC PROGENITOR CELLS IN VIEW OF TRANSPLANTATION | BIOKINE THERAPEUTICS LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| EP-2841084-B1 | CXCR4 ANTAGONIST PEPTIDE FOR USE IN THE TREATMENT OF LARGE CELL LUNG CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2018-05-30 | — | — | EP | disclosed |
| US-9439942-B2 | Peptides and use thereof in the treatment of large cell lung cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2016-09-13 | — | — | US | disclosed |
| US-9427456-B2 | Peptide therapy for increasing platelet levels | BIOKINE THERAPEUTICS LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| EP-3011961-A1 | 4F-benzoyl-TN14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation | Biokine Therapeutics LTD. (IL) | 2016-04-27 | — | — | EP | disclosed |
| EP-2942059-A1 | 4F-BENZOYL-TN14003 FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | Biokine Therapeutics LTD. (IL) | 2015-11-11 | — | — | EP | disclosed |
| US-9034814-B2 | CXCR4 antagonists for wound healing and re-epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2015-05-19 | — | — | US | disclosed |
| WO-2008075369-A2 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY | BIOKINE THERAPEUTICS LTD. (IL) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075371-A2 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR IMMUNOMODULATION | BIOKINE THERAPEUTICS LTD. (IL) | 2008-06-26 | — | — | WO | disclosed |
| EP-1898943-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | Hadasit Medical Research Services & Development Ltd. (IL) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006126188-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2006-11-30 | — | — | WO | disclosed |
| US-20060264605-A1 | Polypeptides having anti-HIV activity and compositions comprising same | BIOKINE THERAPEUTICS LTD. (IL) | 2006-11-23 | — | — | US | disclosed |
| US-7138488-B2 | Polypeptides having anti-HIV activity and compositions comprising same | BIOKINE THERAPEUTICS LTD. (IL) | 2006-11-21 | — | — | US | disclosed |
| US-20040116655-A1 | Novel polypeptides and anti-hiv drugs containing the same | BIOKINE THERAPEUTICS LTD. (IL) | 2004-06-17 | — | — | US | disclosed |
| EP-1323730-A1 | NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME | SEIKAGAKU CORPORATION (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | CXCR4, CXCL12, CXCR5 | ODC1 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.